Jason Coloma Sells 34,501 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total transaction of $907,031.29. Following the transaction, the chief executive officer directly owned 18,151 shares in the company, valued at approximately $477,189.79. The trade was a 65.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Down 3.2%

MAZE traded down $0.85 during trading hours on Thursday, reaching $25.87. 477,427 shares of the stock traded hands, compared to its average volume of 639,798. The firm’s fifty day simple moving average is $28.76 and its two-hundred day simple moving average is $31.34. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -10.27 and a beta of 2.17. Maze Therapeutics, Inc. has a fifty-two week low of $14.16 and a fifty-two week high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on MAZE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. BTIG Research restated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $66.00.

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently modified their holdings of the stock. Royal Bank of Canada grew its stake in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the last quarter. California State Teachers Retirement System raised its stake in Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in Maze Therapeutics by 18.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after buying an additional 931 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in Maze Therapeutics by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock worth $135,000 after buying an additional 977 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.